## Welcome to California Department of Public Health Immunization Branch Afternoon TEAch Webinar




April 26, 2023 12:00PM – 1:00PM





During today's webinar, please use the Q&A panel to ask your questions so CDPH subject matter experts can respond directly.





Resource links will be dropped into, "Chat"



# Housekeeping

#### **Reminder to Panelists:**



- Please mute yourself when not speaking.
- Please monitor the Q&A panel for questions you may be able to answer.

#### **Reminder to Attendees:**



Today's session is being recorded. Access today's slides and archived presentations at: <u>eziz.org</u>




If you have post-webinar questions, please email <a href="mailto:rachel.jacobs@cdph.ca.gov">rachel.jacobs@cdph.ca.gov</a>



## Webinar Objectives:

By the end of the presentation, attendees should be able to:

- Understand updated CDC Advisory Committee for Immunization Practices (ACIP) recommendations for children and adolescents.
- Understand how to meet the AB 1797 requirement.
- Describe how patients can access their Digital Vaccine Record (DVR).
- Identify relevant patient and provider education resources.





# Agenda: Wednesday, April 26, 2023

No.	Item	Speaker(s)	Time (PM)			
1	Welcome	Rachel Jacobs (CDPH)	12:00 – 12:03			
2	Updated CDC ACIP Immunization Recommendations for Children and Adolescents	Samantha Johnston, MD, MPH (CDPH)	12:03 – 12:25			
3	AB 1797 Requirement	Michael Powell, MSc (CDPH)	12:25 – 12:30			
4	Digital Vaccine Record (DVR)	Michael Powell, MSc (CDPH)	12:30 – 12:40			
5	Resources	Terisha Gamboa, MPH (CDPH)	12:40 – 12:45			
6	Q&A	Rachel Jacobs and CDPH Subject Matter Experts (SMEs)	12:45 – 1:00			
Thank you!						



## Updated CDC ACIP Immunization Recommendations for Children and Adolescents

Samantha Johnston, MD, MPH Medical Officer, CDPH Immunization Branch



## Outline

- Routine Immunization Gaps: Filling in "Pandemic Potholes"
- COVID-19 Vaccine News
- CDC Advisory Committee on Immunization Practices (ACIP) 2023 Child/Adolescent Schedule Updates
- Td/Tdap Updates
- Subcutaneous (SC) or Intramuscular (IM) Administration of Merck Live Virus Vaccines
- Rotavirus Formulation Updates



# **Routine Immunization During the Pandemic**


- Large decreases in routine immunization during the early months of the pandemic.
- Gaps have persisted
- Co-administration with COVID-19 vaccine recommended but infrequent
- Pharmacies have immunized:

 $_{\odot}$  Many adults against influenza and COVID-19

• Fewer children against these and other diseases




## Measles, Mumps, and Rubella (MMR) Doses in 4-6-Year-Olds Recorded in CAIR by Week






Weekly Population-Based Rates of COVID-19-Association Hospitalizations among Children and Adolescents Ages 17 Years and Older March 2020-February 2023 (entire pandemic period)





**COVID NET: National Center for Immunization and Respiratory Diseases** 


## COVID-19 Deaths in Children and Adolescents by Age Based on Death Certificate Data January 1, 2020 – February 11, 2023





**CDC ACIP Meeting: Considerations for Bivalent Primary Series** 

## Primary series completion by age group in years, California





**COVID-19 Vaccination Data** 


# **COVID-19 Vaccines**

- Recommended for ALL individuals 6 months
   of age and older
- Monovalent vaccines no longer authorized
- Fall 2023

 $\circ$  Commercialization

o New Formulation?

Resources: <u>CDC ACIP COVID-19 Vaccine Recommendations</u> <u>COVID-19 Vaccine Timing Guide</u> <u>COVID-19 Vaccine eziz.org/covid Page</u> <u>CDC: Stay Up to Date with COVID-19 Vaccines Including Boosters</u>





## Hot Off the Presses! Bivalent Vaccine Authorization and Recommendations for All Doses

- In mid-April, 2023, FDA amended the emergency use authorization (EUA) of Moderna and Pfizer-BioNTech COVID-19 mRNA vaccines to simplify the schedule for most individuals.
- Bivalent mRNA vaccines are authorized and recommended to be used for **ALL doses** for individuals 6 months and older.
- Monovalent Moderna and Pfizer-BioNTech mRNA COVID-19 vaccines are no longer authorized for use in the Unites States.

 $\circ$  Deauthorization is NOT related to safety concerns.

- Additional dose for people 65+ and with certain types of immunocompromise.
- No changes to Novavax monovalent and J&J monovalent vaccines.



Transitioning from the Monovalent to the Bivalent Era: Children without Immunocompromise Aged <u>6 Months – 4 Years</u>

#### **Doses previously recommended:**

## **Doses now recommended:**

#### Moderna:

- 2 monovalent primary series doses +
- 1 bivalent booster dose

#### **Pfizer:**

- 2 or 3 monovalent primary series doses +
- 1 bivalent primary series dose

#### **Customized** by COVID-19 vaccination history such that all children receive:

- At least 2 vaccine doses in total including
- At least 1 bivalent dose

#### Unvaccinated children:

**Pfizer** vaccine should receive 3 bivalent doses in total

**Moderna** should receive 2 bivalent doses in total

#### \*Should receive all doses from the same manufacturer\*



April 19 CDC ACIP Presentation: Updates to Interim Clinical Considerations for Use of COVID-19 Vaccines

Clinical Guidance for COVID-19 Vaccination | CDC

Transitioning from the Monovalent to the Bivalent Era: Children without Immunocompromise Aged <u>5 Years</u>

**Doses previously recommended:** 

#### Moderna:

- 2 monovalent primary series doses +
- 1 bivalent booster dose

#### **Pfizer:**

- 2 or 3 monovalent primary series doses +
- 1 bivalent primary series dose

#### **Customized** so that **Moderna**

**Doses now recommended:** 

recipients receive:

- At least 2 vaccine doses in total including
- At least **1 bivalent** dose

#### And **Pfizer** recipients receive:

• At least 1 bivalent dose

#### Unvaccinated children:

**Pfizer** vaccine should receive 1 bivalent doses in total

**Moderna** should receive 2 bivalent doses in total

#### \*Should receive all doses from the same manufacturer\*



April 19 CDC ACIP Presentation: Updates to Interim Clinical Considerations for Use of COVID-19 Vaccines

Clinical Guidance for COVID-19 Vaccination | CDC

New Recommendations for People Aged 6 Years and Older Without Immunocompromise Who Have Not Yet Received a Bivalent mRNA Dose




**Most individuals** who have already received a single bivalent dose are **not** currently eligible for another dose.



April 19 CDC ACIP Presentation: Updates to Interim Clinical Considerations for Use of COVID-19 Vaccines


New Recommendations for People Aged 6 Years and Older Without Immunocompromise Who Have Not Yet Received a Bivalent mRNA Dose, Regardless of COVID-19 Vaccination History





April 19 CDC ACIP Presentation: Updates to Interim Clinical Considerations for Use of COVID-19 Vaccines

New Flexibility for People at Higher Risk of Severe COVID-19: People Aged 6 Years and Older *With Immunocompromise* Who Have Already Received a Bivalent mRNA Dose






**COVID-19** Vaccines

April 19 CDC ACIP Presentation: Updates to Interim Clinical Considerations for Use of

## People at Higher Risk of Severe COVID-19: People Aged 65 Years and Older





April 19 CDC ACIP Presentation: Updates to Interim Clinical Considerations for Use of COVID-19 Vaccines

## **Detailed Information on COVID-19 Vaccines**

For detailed clinical, storage & handling, and vaccine management updates on COVID-19 vaccines, attend the Friday Provider Webinar, every week at 9 AM – 10:30 AM P.T.

#### Register here

Detailed tables for children aged 6 months – 4 years and aged 5 years can be found here:

CDC Clinical Guidance for COVID-19 Vaccination



## Commercialization: U.S. Health and Human Services (HHS)

- Commercialization timeline is unrelated to declarations of public health emergency (to end 5/11/2023)
- Anticipate transition of vaccines to a "more traditional pathway" for procurement, distribution, and payment in early Fall 2023.
- Public health continues distribution of federally-purchased supplies until utilized or expired
- Vaccines will remain free for most U.S. residents through various sources
  - Vaccines for Children (VFC), Children's Health Insurance Program (CHIP), most commercial insurance, Medicare, Medicaid
- Vaccine may be sold if either licensed or EUA\* from FDA<sup>^</sup>
- Cost sharing: Unclear as yet



## 2023 CDC ACIP Child/Adolescent Schedule

- **COVID-19**: Primary and booster doses now included in routine IZ schedule.
- Influenza: Live vaccine should not be given to close contacts of immunosuppressed persons requiring a protected environment.
- MMR:
  - New formulation of MMR (Priorix/GSK) FDA licensed/ACIP recommended
  - $_{\odot}$  Measles, mumps, rubella, and varicella (MMRV) added as an option in the MMR row
  - $_{\odot}$  Additional dose recommended during a mumps outbreak



<u>CDC ACIP Recommendations - Use of a Third Dose of Mumps Virus–Containing Vaccine in</u> <u>Persons at Increased Risk for Mumps During an Outbreak</u>

## 2023 CDC ACIP Child/Adolescent Schedule

### Pneumococcal

- PCV 15 and PCV 13 may be used interchangeably for healthy and immunocompromised children.
- The 4<sup>th</sup> dose "is only necessary for children aged 12–59 months regardless of risk, or aged 60–71 months with any risk, who received 3 doses before age 12 months."



2023: Pneumococcal Conjugate Vaccine (PCV) - Catch-up Guidance for Healthy Children 4 months through 4 years of Age

## Catch-Up Guidance for Healthy Children 4 Months through 4 Years of Age: Pneumococcal Conjugate Vaccine (PCV)

IF current age is	AND # of previous doses is	,	AND	THEN	Next dose due <sup>2</sup>	IF current age is	AND # of previous doses is	AND	AND	THEN	Next dose due <sup>2</sup>	IF current age is	AND # of previous doses is	AND	AND	AND	THEN	Next dose due <sup>2</sup>
4 through 6 months	0 or unknown 1	→	→	Give Dose 1 today	Give Dose 2 at least 4 weeks after Dose 1		0 or unknown 1	→	<b>→</b>	Give Dose 1 today	Give Dose 2 ( <b>Final Dose</b> ) at least 8 weeks after Dose 1		0	→	→	→	Give Dose 1 today	No additional doses needed
		<b>→</b>	It has been at least 4 weeks since Dose 1		Give Dose 3 at least 4 weeks after Dose 2			Dose 1 was given <b>before</b> 12 months of age	It has been at least 4 weeks since Dose 1		Give Dose 3 (Final Dose) at least 8 weeks after Dose 2		<u> </u>	Dose 1 was			Give Dose 2	
		→	It has <b>not</b> been at least 4 weeks since Dose 1	No dose today	Give Dose 2 at least 4 weeks after Dose 1				It has <b>not</b> been at least 4 weeks since Dose 1		Give Dose 2 at least 4 weeks after Dose 1			given <b>before</b> 1 <sup>st</sup> birthday	→	→	(Final Dose) today	No additional doses needed
	2	<b>→</b>	It has been at least 4 weeks since Dose 2	Give Dose 3 today	Give Dose 4 ( <b>Final Dose</b> ) at 12 months of age or older			Dose 1 was given at 12 months of age or older	It has been at least 8 weeks since Dose 1	Give Dose 2 ( <b>Final Dose</b> ) today	No additional doses needed				Dose 1 was given	It has been at least 8 weeks since Dose 1	Give Dose 2 (Final Dose) today	No additional doses needed
		<b>→</b>	It has <b>not</b> been at least 4 weeks since Dose 2	No dose today	Give Dose 3 at least 4 weeks after Dose 2				It has <b>not</b> been at least 8 weeks since Dose 1		Give Dose 2 ( <b>Final Dose</b> ) at least 8 weeks after Dose 1		'	Dose 1 was given after 1st birthday	before 2 <sup>nd</sup> birthday	It has <b>not</b> been at least 8 weeks since Dose 1	No dose today	Give Dose 2 (Final Dose) at least 8 weeks after Dose 1
7 through 11 months	0	$\rightarrow$	$\rightarrow$	Give Dose 1 today	Give Dose 2 at least 4 weeks after Dose 1			Both doses were given <b>before</b> 12 months of age At least one dose was given at 12 months of age or older	It has been at least 8 weeks since Dose 2	Give Dose 3 ( <b>Final Dose</b> ) today	No additional doses needed				Dose 1 was given	→	No dose today	No additional doses
	1		It has been at least 4 weeks since Dose 1	Give Dose 2 today	Give Dose 3 (Final Dose) at least 8 weeks after Dose 2 and				It has <b>not</b> been at least 8 weeks	No dose todav	Give Dose 3 (Final Dose) at least 8 weeks after Dose 2 No additional doses needed Give Dose 3 (Final Dose) at least 8 weeks after Dose 2		L	after 2 <sup>nd</sup> birthday			needed	
		Dose 1 was given <b>before</b> 7 months of age	It has <b>not</b> been		at 12 months of age or older	23 months 23 months 24 least 25 months 23 months 23 months 23 months 23 months 23 months 24 least 23 months 24 least 23 months 24 least 24 least 25 months 26 least 27 months 28 least 29 least 20 least 20 least 20 least 20 least 21 least 23 months 24 least 24 least 23 months 24 least 24 least 25 months 26 least 27 months 27 months 28 least 29 least 20 least			since Dose 2	Give Dose 3				Dose 1 was given <b>before</b>	Dose 2 was given before 1st birthday	→	Give Dose 3 (Final Dose)	No additional doses needed
			at least 4 weeks since Dose 1	No dose today	4 weeks after Dose 1				8 weeks since Dose 2	(Final Dose) today						Dose 2 was	today Give Dose 3	
		Dose 1 was given at 7 months of age or older	It has been at least 4 weeks since Dose 1	Give Dose 2 today	Give Dose 3 (Final Dose) at least 8 weeks after Dose 2 and at 12 months of age or older				onths of r older at least 8 weeks since Dose 2 doses given at						Dose 2 was given <b>after</b> 1 <sup>st</sup> birthday	given <b>before</b> 2 <sup>nd</sup> birthday	(Final Dose) today	No additional doses needed
			It has <b>not</b> been at least 4 weeks since Dose 1	No dose today	Give Dose 2 at least 4 weeks after Dose 1			Both doses were given at 12 months of age		No dose today	dose today No additional doses needed					Dose 2 was given <b>after</b> 2 <sup>nd</sup> birthday	No dose today	No additional doses needed
	2	Dose 2 was	It has been at least 4 weeks since Dose 2	Give Dose 3 today	Give Dose 4 ( <b>Final Dose</b> ) at least 8 weeks after Dose 3 <b>and</b> at 12 months of age or older			or older <sup>3</sup>	It has been at least 8 weeks since Dose 3	Give Dose 4 ( <b>Final Dose</b> ) todav	No additional doses needed			Dose 1 was given after 12 months of age	→	→	No dose today	No additional doses needed
		given <b>before</b> 7 months of age	It has <b>not</b> been at least 4 weeks No dose today since Dose 2	Give Dose 3 at least 4 weeks after Dose 2		3	All doses were given <b>before</b> 12 months of age	It has <b>not</b> been at least 8 weeks since Dose 3	No dose today	Give Dose 4 ( <b>Final Dose</b> ) at least 8 weeks after Dose 3			All 3 doses were given <b>before</b> 12 months of age	→	->	Give Dose 4 ( <b>Final Dose</b> ) today	No additional doses needed	
		Dose 2 was given at 7 months of age or older	<b>→</b>	No dose today	Give Dose 3 ( <b>Final Dose</b> ) at least 8 weeks after Dose 2 <b>and</b> at 12 months of age or older		5	1 or more doses were given at 12 months of age or older		No dose today	No additional doses needed		3	1 or more doses were given at 12 months of age or older	→	→	No dose today	No additional doses needed



2023: Pneumococcal Conjugate Vaccine (PCV) - Catch-up Guidance for Healthy Children 4 months through 4 years of Age

## 2023 CDC ACIP Child/Adolescent Schedule

- **Dengue**: NOT recommended for non-residents of endemic areas
- Hepatitis B: Language added on recommendations for infants born to mothers who are HBsAg + or unknown.
- **HPV**: NOT recommended during pregnancy
- Meningococcal ACWY: Menveo one-vial formulation should not be given prior to 10 years.
- Meningococcal B:
  - $\circ$  A 3rd dose of **Trumenba** is not needed if 2<sup>nd</sup> dose is given  $\geq$ 6 months after the 1<sup>st</sup> dose.
  - $\circ$  A 4<sup>th</sup> dose should be given <u>></u>4 months after the 3<sup>rd</sup> dose **IF** the 3<sup>rd</sup> dose is given earlier than 4 months after the 2<sup>nd</sup> dose.
- Polio: Recommendations added for adults at increased risk for exposure to polioviruses: Polio Vaccination Recommendations for Specific Groups



# Subcutaneous (SC) or Intramuscular (IM) Administration of Merck Live Virus Vaccines

- MMRII, ProQuad, and Varivax, all manufactured by Merck, may now be given either subcutaneously OR intramuscularly.
- A single dose of each vaccine remains at ~0.5mL.
  - <u>Package Insert (Refrigerated) ProQuad (fda.gov)</u>
  - Package Insert MMRII (fda.gov)
  - Package Insert Varivax (Refrigerator) (fda.gov)



# Use of Tdap in Lieu of Td

- Tdap vaccine is an acceptable alternative to Td vaccine, including for wound management, except in very rare cases of a specific contraindication to pertussis-containing vaccines.
- Supplies of Td vaccine should be preserved for those with contraindications to pertussis-containing vaccines.
- CDC recommends that vaccination providers transition to use of Tdap vaccine in lieu of Td vaccine whenever possible.



## New Formulation of Rotarix

- In November 2022, FDA approved a fully liquid, oral dosing only presentation of Rotarix vaccine.
- A single dose of the new liquid formulation is 1.5mL (compared to 1 mL of the old formulation).
- The "oral dosing only formulation" does NOT require reconstitution.



## AB 1797 Requirement

Michael Powell, MSc

Chief of Registry & Assessment Section, CDPH Immunization Branch



## Participation in Immunization Information Systems (IIS) Now Mandatory

With the passage of <u>AB 1797</u>, effective January 1, 2023, California healthcare providers who administer vaccines are required to enter:

- All administered immunizations into the IIS, either <u>California Immunization Registry</u> (CAIR) or <u>Healthy Futures/RIDE</u>
- Race and ethnicity information for each patient in the IIS to support assessment of health disparities and immunization coverage

Submitting doses in the ISS helps providers meet participation requirements for Medi-Cal and VFC programs. See <u>CDPH Letter to California VFC Providers: AB 1797</u>.



## Submit Historical Doses to an IIS

- Historical vaccinations are either vaccinations given by your site in the past (that have not been added to CAIR as new immunizations) or those given by another provider that were never added to CAIR (i.e., are on the patient's Yellow Card, but are not in CAIR).
- There are important benefits to submitting historical doses for your patients to CAIR.
  - Having complete patient records in CAIR is essential to ensuring future vaccine recommendations are accurate.
  - As more immunization data are submitted to CAIR and patient records become more complete, more people will access their immunization records through the <u>Digital Vaccine Record (DVR)</u> <u>portal</u>. This will help reduce requests from your patients for their immunization records.





## Submit Historical Doses to an IIS

- To submit historical vaccinations through data exchange (DX), please work with your EHR vendor support and a CAIR Data Exchange Specialist (<u>CAIRDataExchange@cdph.ca.gov</u>) to discuss submission options.
- **To manually enter historical vaccines**, consult the <u>CAIR2 Guide to Adding Historical</u> <u>Immunizations</u> (PDF) or view the <u>Adding Historical Immunizations</u> video.
- Providers in Alpine, Amador, Calaveras, Mariposa, Merced, San Joaquin, Stanislaus, or Tuolumne counties will need to report historical vaccinations to <u>Healthy Futures/RIDE</u>. For assistance, contact the Healthy Futures/RIDE Help Desk at (209) 468-2292 or <u>support@myhealthyfutures.org</u>.





# AB 1797 Resources

- FAQs page
- Short <u>video</u> highlighting benefits of using CAIR
- Run <u>doses administered report</u>

   See <u>CAIR user guides</u> to enter doses correctly

#### Prepare for the New Immunization Registry Requirement

#### What is the new requirement?

AB 1797, a California bill effective January 1, 2023, requires providers to enter immunizations they administer as well as a patient's race and ethnicity into a California immunization registry (CAIR or HealthyFutures/RIDE).



#### Where can I learn more? Visit <u>bit.ly/AB1797FAQ</u>.



#### **Enroll Now**

There are many benefits to participating in an immunization registry. To learn more, visit <u>bit.ly/CAIRvideo</u> or to start the enrollment process, visit <u>cairweb.org</u>.

Providers in Alpine, Amador, Calaveras, Mariposa, Merced, San Joaquin, Stanislaus, or Tuolumne counties will need to enroll in Healthy Futures/RIDE (<u>www.myhealthyfutures.org</u>). For assistance, contact the Healthy Futures/RIDE Help Desk at (209) 468-2292 or <u>support@myhealthyfutures.org</u>.



We are here to support you along the way Questions? <u>CAIRHelpdesk@cdph.ca.gov</u> Phone: 800-578-7889



## Digital Vaccine Record (DVR)


Michael Powell, MSc

Chief of Registry & Assessment Section, CDPH Immunization Branch



## **Digital Vaccine Record (DVR)**

#### Residents can now retrieve both their COVID-19 Vaccine Records and California Immunization Records



#### **New Features!**

- Expanded to include all routine immunizations
- Shows vaccines that may be overdue
- Available in multiple languages
- May be used as documentation for school immunization requirements



#### https://MyVaccineRecord.cdph.ca.gov

## Overdue, Upcoming, and Complete Vaccines

ne: Patient Zero	Date o	f Birth: 09/26/202	20	Date Issued: 03/01/20	
ronavirus (COVID-19)	Overdue 09/17/2022				
Vaccine	Dose	Date Given	Age Given	Clinic that Administered or Transcribed	
fizer mRNA LNP-S PF 6M<5Y	1	06/30/2022	1y 9m 4d	Fairway Children's Medical Group	
fizer mRNA LNP-S PF 6M<5Y	2	07/23/2022	1y 9m 27d	Fairway Children's Medical Group	
ohtheria, Tetanus, Ace	llular Pertuss	sis (DTP/aP)	Next Dose Due 09/26/2024		
Vaccine	Dose	Date Given	Age Given	Clinic that Administered or Transcribed	
DTaP-HepB-IPV	1	11/30/2020	0y 2m 4d	YORBA LINDA OFFICE	
DTaP-HepB-IPV	2	01/27/2021	0y 4m 1d	YORBA LINDA OFFICE	
DTaP-HepB-IPV	3	04/09/2021	0y 6m 14d	YORBA LINDA OFFICE	
DTaP	4	07/06/2022	1y 9m 10d	YORBA LINDA OFFICE	
patitis A (HepA)				Complete	
Vaccine	Dose	Date Given	Age Given	Clinic that Administered or Transcribed	
HepA-Ped 2 Dose	1	09/28/2021	1y 0m 2d	YORBA LINDA OFFICE	
HepA-Ped 2 Dose	2	07/06/2022	1y 9m 10d	YORBA LINDA OFFICE	
patitis B (HepB)				Complete	
Vaccine	Dose	Date Given	Age Given	Clinic that Administered or Transcribed	
HepB-Peds	1	09/27/2020	Oy Om 1d	YORBA LINDA OFFICE	
DTaP-HepB-IPV	2	11/30/2020	0y 2m 4d	YORBA LINDA OFFICE	
DTaP-HepB-IPV	Invalid	01/27/2021	0y 4m 1d	YORBA LINDA OFFICE	
DTaP-HepB-IPV	3	04/09/2021	0y 6m 14d	YORBA LINDA OFFICE	



## **Recommended Vaccines Section**

This section displays towards the bottom of the DVR if a resident is overdue for a 1<sup>st</sup> dose, or if a 1<sup>st</sup> dose of a vaccine group is due within one year.


lame: Patient Zero	Date of Birth: 07/26/2018	Date Issued: 03/01/2023				
Recommended vaccinations we do not see in your record (future recommen- dations shown in yellow are due within one year):						
Vaccine Group	Recommended Date					
<ul> <li>Coronavirus (COVID-19)</li> </ul>	03/01/2023					
	ayed on your DVR are based on guideling healthcare provider may make different					



## **DVR Mobile Experience**

The enhanced Mobile Experience provides residents with a more intuitive mobile interface view of their DVR – displaying the same information in an easier-to-read, mobile browser friendly format.

Residents have more control over the information they choose to share.







# **Digital Vaccine Record Flyer**

- Consider posting in your clinics and sharing with your patients
- Includes a QR code directing to <u>Digital</u> <u>Vaccine Record (ca.gov)</u>
- English and Spanish versions available



GET YOUR DIGITAL VACCINE RECORD



Para más preguntas sobre el DVR, visite myvaccinerecord.cdph.ca.gov/faq-es/ o llame al 1-833-422-4255 (L-V 8AM-8PM, S-D 8AM-5PM).

California Department of Public Health, Immunization Branch

poder obtener su DVR cuando se le

proporcione el enlace a su registro

IMM-14615 (3/30/23)

Digital Vaccine Record Flyer

Spanish Version



## **Additional Resources**

Terisha Gamboa, MPH

Health Educator, CDPH Immunization Branch



# **Job Aids for Pediatric Providers**


CDC ACIP's Best Practice Guidelines for Immunization


## • CDPH

- o Pneumococcal Timing Guide for Children
- o IZ Timing Guide for Infants and Children just updated!
- o IZ Schedule with Combination Vaccines
- o IZ Info and Timing Brochure for Parents



	dard	PCV13 Prevnar <sup>®</sup> or PCV15	PCV13 Prevnar* o PCV15	or Prevni	r* or	PCV13 Prevnar <sup>+</sup> or PCV15
	Age:	Vaxneuvance* 2 months	Vaxneuvan 4 month			Vaxneuvance*
Catch-			nd timing of past doses.	underlying conditions	Page of the stress	
		-	-			
Age 2	2-18 Year	rs With Լ	Inderlying	Condition	(s)	
			PSV23 at the same visit. 3 or PCV15 before givin			
<ul> <li>Prior d</li> </ul>	loses count toward	ls doses recomme	nded below and do not	t need to be repeated.		
	13 or PCV15 series needed.	completed previo	usly, or at least 1 dose g	given at age 6 years or o	ider, no additiona	PCV13 or
			weeks before giving PC	2V13 or PCV15. fore giving a second do	a af 0051/33	
• No mo	re than two doses		mended before age 65 y		se 01 FF 3v 25.	
				rears.		
				years.		
	nic conditions:	:		rears.	Children your	oer than 6 years
• Dia	betes		r cvanotic disease)	PPSV	of age should	iger than 6 years have received
• Dial • Hea • Lun	betes Int Disease (parti Ig disease (exclu	icularly failure oi ding asthma, un		PPSV 23	of age should the standard of PCV13 or P	have received or catch-up doses CV15 described
- Dial - Hea - Lun imn	betes art Disease (parti g disease (exclu nunocompromisi	icularly failure o ding asthma, un ed by prolonged	less	PPSV 23 Pneumovax*2	of age should the standard of PCV13 or P	have received or catch-up doses
- Dial - Hea - Lun imn	betes Int Disease (parti Ig disease (exclu	icularly failure o ding asthma, un ed by prolonged	less	PPSV 23	of age should the standard of PCV13 or P	have received or catch-up doses CV15 described
Dial     Hea     Lun     imn     cort	betes art Disease (parti og disease (exclu nunocompromise cicosteroids – see	cularly failure o ding asthma, un ed by prolongec below)	less	PPSV 23	of age should the standard of PCV13 or P	have received or catch-up doses CV15 described
Dial     Hea     Lun     imm     cort  B. Immu (includ)	betes Int Disease (parti Ig disease (exclu nunocompromis icosteroids – see unocompromis ding HIV infectior	icularly failure o ding asthma, un ed by prolonged below) ed n or	less	PPSV 23	of age should the standard of PCV13 or P	have received or catch-up doses CV15 described
Dial     Hea     Lun imm cort  B. Immu (includ immu	betes Int Disease (parti Ig disease (exclu nunocompromis icosteroids – see unocompromis ding HIV infectior nosuppressive tr	icularly failure or ding asthma, un ed by prolonged below) eed n or eatments),	less I high-dose oral	PPSV 23	of age should the standard of PCV13 or P	have received or catch-up doses CV15 described
Dial     Hea     Lun imm cort  B. Immu (includ immu Hemo	betes Int Disease (parti Ig disease (exclu nunocompromis icosteroids – see unocompromis ding HIV infectior	icularly failure o ding asthma, un ed by prolongec below) eed n or eatments), sease),	less I high-dose oral PCV13 Prevna* or PCV15 8 we	PPSV 23 Preumovar*2 eks PPSV 23	of age should the standard of PCV13 or P above before 5 years	have received sr catch-up doses (V15 described receiving PPSV23. PPSV 23
Dial     Dial     Hea     Lun     imm     cort  B. Immu     (includ     immu     Hemo     (includ     Asple	betes int Disease (parti ig disease (exclu nunocompromisi iccosteroids – see unocompromisi ding HIV infection nosupressive tri oglobinopathy ding sickle cell di enia,	icularly failure oi ding asthma, un ed by prolonged below) eed n or eatments), , sease), v	less I high-dose oral PCV13 Prevnet <sup>a</sup> or	PPSV 23 Preumovar 2 PPSV	of age should the standard of PCV13 or P above before 5 years	have received or catch-up doses CV15 described
Dial     Hea     Lun     imm     cort  B. Immu     (includ     immu     Hemo     (includ     Asple     Chron	betes Int Disease (parti g disease (exclu unocompromisi cicosteroids – see ding HIV infection nosuppressive tr oglobinopathy ding sickle cell di mia, nic renal failur	cularly failure or ding asthma, un ed by prolonged below) eetments), sease), sease), e, or	less I high-dose oral PCV13 Prevna* or PCV15 8 we	PPSV 23 Preumovar*2 eks PPSV 23	of age should the standard of PCV13 or P above before 5 years	have received sr catch-up doses (V15 described receiving PPSV23. PPSV 23
Dial     Hea     Lun     imm     cort  B. Immu     (includ     immu     Hemo     (includ     Asple     Chron	betes int Disease (parti ig disease (exclu nunocompromisi iccosteroids – see unocompromisi ding HIV infection nosupressive tri oglobinopathy ding sickle cell di enia,	cularly failure or ding asthma, un ed by prolonged below) eetments), sease), sease), e, or	less I high-dose oral PCV13 Prevna* or PCV15 8 we	PPSV 23 Preumovar*2 eks PPSV 23	of age should the standard of PCV13 or P above before 5 years	have received sr catch-up doses (V15 described receiving PPSV23. PPSV 23
Dial     Hea     Lun     imm     cort  B. Immu     (includ     immu     Hemo     (includ     Asple     Chron	betes Int Disease (parti g disease (exclu unocompromisi cicosteroids – see ding HIV infection nosuppressive tr oglobinopathy ding sickle cell di mia, nic renal failur	cularly failure or ding asthma, un ed by prolonged below) eetments), sease), sease), e, or	less I high-dose oral PCV13 Prevna* or PCV15 8 we	PPSV 23 Preumovar*2 eks PPSV 23	of age should the standard of PCV13 or P above before 5 years	have received sr catch-up doses (V15 described receiving PPSV23. PPSV 23
Dial     Hea     Lun     imm     cort  B. Imms     (incluc     immu     Hemo     (incluc     Asple     Chron     Neph  C. CSF Id	betes Int Disease (parti Ing disease (exclu) unaccompromisis closeteroids – see unocompromisis ding HIV infection nosuppressive thr oglobinopathy ding sickle cell di enia, inic renal failurur protic syndrom eaks or	cularly failure or ding asthma, un ed by prolonged below) eetments), sease), sease), e, or	less I high-dose oral PCV13 Prevna* or PCV15 8 we	PPSV 23 Preumovar*2 eks PPSV 23	of age should the standard of PCV13 or P above before 5 years	have received sr catch-up doses (V15 described receiving PPSV23. PPSV 23
Dial     Hea     Lun     imm     cort  B. Imms     (incluc     immu     Hemo     (incluc     Asple     Chron     Neph  C. CSF Id	betes Int Disease (parti ig disease (exclu hunocompromisi costeroids – see unocompromisi ding HIV infection nosuppressive tin nosuppressive tin ania (scke cell di mia, nic renal failur irotic syndrom	cularly failure o ding asthma, un ed by prolonged below) eed a ar eatments), sease), e, or e	less high-dose oral PCV13 Prevurary PCV15 avreeurance	PPSV 233 Presmovar*2	of age should the standard of PCV13 or P above before 5 years	have received sr catch-up doses (V15 described receiving PPSV23. PPSV 23







# Vaccine Fact Sheets

- MMR
  - MMR-II (Merck) now intramuscular administration
  - Priorix (GSK)
- Other Merck products that are now subcutaneous and intramuscular administration
  - ProQuad (MMRV)
  - Varivax (Varicella/chickenpox)
- Rotavirus
  - Rotarix (GSK)
  - RotaTeq (Merck)

## **Updates coming soon!**

#### **Vaccine Fact Sheet** Rotavirus RotaTeo® Brand Name and Manufacturer Rotarix® Merck GlaxoSmithKline (GSK Protects Against Rotavirus Rotavirus Routine Schedule 2-dose series at age 2 and 4 months 3-dose series at age 2, 4, and 6 months Minimum Intervals 4 weeks minimum interval between dose 1 and 2 4 weeks between dose | and 2: 4 weeks between dose 2 and 3 ved for use in Infants 6 weeks to 24 weeks of age. Infants 6 weeks to 32 weeks of age. https://www.fda.gov/vaccines-blood-biologics/vachttps://www.fda.gov/vaccines-blood-biologics/vaccines/rotarix Administration Oral Oral Packaging ROTARIX oral dosing applicator only presentation is Vaccine is packaged as 10 single-dose, ready-to-use 2mL supplied as a single, 1.5-mL dose in a prefilled oral dospouches ing applicator with a plunger stopper (NDC 58160-740-02) in a carton of 10 (NDC 58160-740-21) Storage Store refrigerated at 36° to 46°F (2° to 8°C)... Refrigerate between 36°F and 46°F (2°C to 8°C) DO NOT FREEZE DO NOT FREEZE Full ACIP Recommendations https://www.cdc.gov/vaccines/hcp/acip-recs/vacc specific/rotavirus.html specific/rotavirus.html Minimum age of first dose: 6 weeks and 0 days Minimum age of first dose: 6 weeks and 0 days Maximum age of first dose: 14 weeks and 6 days Maximum age of first dose: 14 weeks and 6 days Maximum age of last dose: 8 months and 0 days Maximum age of last dose: 8 months and 0 days VFC Letter https://www.cdc.gov/vaccines/hcp/acip-recs/vacc specific/rotavirus.html Billing Codes CHDP code: 81 CHDP code: 75 CPT code for vaccine: 90681 CPT code for vaccine: 90681 CPT code for administration\*: 90460 CPT code for administration\*: 90460 Medi-Cal Fee-For-Service (FFS) administration: 90681 Medi-Cal Fee-For-Service (FFS) administration: 90681 with modifiers -SK (high-risk) and -SL (VFC) with modifiers -SK (high-risk) and -SL (VFC) ICD-10-CM code (encounter for immunization): Z23 ICD-10-CM code (encounter for immunization): Z23 \*https://gskpro.com/en-us/therapy-areas/vaccines/ Comments • Licensed in 2008 Licensed in 2006 Infants with severe latex allergies should not receive Do not begin series in infants older than 14 weeks, Rotarix. 6 days of age · Infants diagnosed with severe combined immunode- · Infants diagnosed with severe combined immunodeficiency disease (SCID), a history of intussusception, ficiency disease (SCID) or a history of intussuscepor a history of uncorrected gastrointestinal tract tion should not receive RotaTeo. congenital malformation that would predispose to intussuscention should not receive Rotarix The lot number to be recorded should be taker from the label on the package/box. ,©VFC EZIZ.OR



## **Updated** COVID-19 Talking Points for Pediatric Providers

Recommending COVID-19 Vaccination and Boosters: Clinical Talking Points for Providers of Pediatric Services



This resource is designed to help you and your staff have effective conversations with families about COVID-19 vaccines, as you are the <u>most trusted source</u> of medical information for families.

### Families can benefit by discussing COVID-19 vaccination.

The top reason parents cite for not vaccinating their children is needing more information. For families who may be hesitant about the COVID-19 vaccine, begin the conversation by asking, "*How do you feel about your child getting the COVID-19 vaccine*?" The goals of these conversations are to have a cordial discussion, answer questions, understand and acknowledge any fears they express, and provide accurate information.



IMM-1431 (4/10/23)

#### Validate parental concerns and answer questions without judgement.

As their child's provider, your guidance is influential. Hearing from you that immunization is safe and effective can be reassuring. When parents express hesitation, ask about and acknowledge their concerns. For example, "if I heard those things, I would be scared, too. Let's talk about your concerns." Let parents know that you share their goal of Keeping their children safe.

#### Give parents accurate information.

Here are common questions and talking points to help parents. Praise parents who ask questions for wanting to know more. Wrap up the conversation by making a recommendation while acknowledging their authority in deciding for their children. For example, "*i think getting vaccinated is best for your child. Ultimately, it's your choice. I'm here to guide you and answer your questions.*"

#### Why should my child get the COVID-19 vaccine and the updated (bivalent) COVID-19 booster?

- It's effective. The vaccines do not protect against all COVID-19 infection, but multiple studies have shown it is effective, especially in preventing severe illness and hospitalization, including against newer variants. (See the following links for additional data: <u>3-to-5-year-olds</u>, <u>5-to-11-year-olds</u>, <u>5-to-11-year-olds</u>, <u>5-to-11-year-olds</u>, <u>5-to-11-year-olds</u>, <u>12-to-18-year-olds</u>, <u>and <u>5-to-17-year-olds</u>, <u>5-to-11-year-olds</u>, <u>5-to-11-year-olds</u>, <u>5-to-11-year-olds</u>, <u>12-to-18-year-olds</u>, <u>and <u>5-to-17-year-olds</u>, <u>5-to-17-year-olds</u>, <u>5-to-11-year-olds</u>, <u>5-to-11-year</u></u></u>
  - Healthy children can have severe COVID-19, too. In fact, <u>almost half</u> of children younger than 18 years hospitalized with COVID-19 have had no prior health problems.
  - Children with pre-existing conditions are at higher risk for severe COVID-19 outcomes.
     Vaccination is especially recommended to keep children with chronic conditions and disabilities safe and healthy.
- <u>Multisystem Inflammatory Syndrome in Children</u> (MIS-C) is a serious condition that can happen in children after infection with COVID-19, even if they had mild symptoms or no symptoms at all. The best way to prevent MIS-C is to protect against SARS-CoV-2 infection through vaccination and other preventive actions.

1 | California COVID-19 Vaccination Program

## Recommending COVID-19 Vaccination and Boosters: Clinical Talking Points

### for Providers of Pediatric Services

 The COVID-19 vaccine lowers the risk of MIS-C by <u>91%, according to data from July-December</u> 2021. In children 5 to 18 years of age, vaccination was associated with a reduced chance of getting MIS-C during the Omicron period.

Vaccinate

IMM-1431 (4/10/23)

**ALL 58** 

- In California, there have been over 1,000 cases of MIS-C, many of which were admitted to an ICU (as of 12/19/22).
- Long COVID affects children and adolescents. Children have reported <u>ongoing respiratory, cardiac,</u> <u>neurologic, and other symptoms</u> following COVID-19 infection. <u>Research</u> suggests that people who are vaccinated against COVID-19 are less likely to develop long COVID.
  - In a study of over 3 million children and adolescents, those infected with COVID-19 were more likely to develop <u>diabetes</u>, cardiovascular disorders including blood clots and myocarditis, and kidney disease than those without COVID-19.

#### Isn't it true that COVID-19 doesn't affect children?

 Unfortunately, no. As of January 2023 COVID-19 has caused more than <u>15 million children in the US to</u> become ill, <u>more than 180,000 to be hospitalized</u>, and <u>more than 2,000 to die</u>.

#### My child already had COVID-19, aren't they protected through natural immunity?

- Even if your child has had COVID-19, you should still get your child vaccinated.
  - Getting a COVID-19 vaccine after having COVID-19 provides added protection against the virus that causes COVID-19.
- People who already had COVID-19 and do not get vaccinated after their recovery are more likely to get COVID-19 again than those who get vaccinated after their recovery.
- If your child recently had COVID-19, you may consider delaying your child's next vaccine dose (primary
  dose or booster) by 3 months from when their symptoms started, or if there were no symptoms, from
  when your child tested bositive.

#### Are COVID-19 vaccines and boosters safe for my child?

- COVID-19 vaccines are safe. Over 260 million people, including over 31 million children, have safely
  received the COVID-19 vaccine in the United States and are now protected against serious COVID-19
  infection. This includes nearly 3 million dosse of the updated booster given to children. Getting
  vaccinated is much safer than the risks of getting sick with COVID-19.
- Mild to moderate side effects are common and can be a sign that your body is building up its defenses to protect you. It's not unusual for a child to feel sore at the injection site or have a fever, headache, and fatigue for a day or two after vaccination.
  - COVID-19 vaccine safety monitoring of over 22,000 children under 5 years old showed vaccination is safe, as have studies in older children (5-11 years old) and adolescents.
  - <u>Early safety findings</u> for the updated (bivalent) booster in children are similar to those
    described for monovalent booster vaccination. The most common side effects reported are
    soreness at injection site, fatigue, and headache.

2 | California COVID-19 Vaccination Program

3 | California COVID-19 Vaccination Program

IMM-1431 (4/10/23)



## COVID-19 Clinical Talking Points for Pediatric Providers (IMM-1431)

### Recommending COVID-19 Vaccination and Boosters: Clinical Talking Points for Providers of Pediatric Services



#### What about myocarditis?

- Myocarditis, or inflammation of the heart, is a rare side effect of some COVID-19 vaccines, but in children, myocarditis has been very rare.
  - In children 5-11 years old, the risk of myocarditis from COVID-19 vaccination is about <u>1 in 1</u> million.
  - This risk is higher in male teens, <u>about 7-10 in 100,000</u>, however the risk of myocarditis is <u>much</u> higher from COVID-19 infection than it is from the vaccine, and myocarditis is usually much more serious after COVID-19 infection than after immunization.
    - This risk can be reduced by a longer interval time between primary series 1<sup>st</sup> and 2<sup>nd</sup> doses, such as 8 weeks.

#### Can COVID-19 vaccines affect my child's fertility?

- The vaccines, including vaccine ingredients or antibodies made following vaccination, have not been shown to affect fertility.
  - <u>Studies</u> show that vaccinated women can get pregnant at the same rates as women who are unvaccinated. A <u>study</u> of more than 2,000 females and their partners found that COVID-19 vaccination did not affect fertility. A <u>recent small study of 45 healthy men</u> also did not show any effects of COVID-19 vaccination on fertility.
  - A study of nearly 4,000 people found a very small, temporary change in menstrual cycle length
    after vaccination. Periods were late by less than 1 day on average and returned to normal
    within 1 or 2 months. The changes were temporary and not clinically significant, meaning there
    was no impact on reproductive health or fertility.
- Hundreds of thousands of people who are pregnant or trying to get pregnant have safely received the COVID-19 vaccine.

#### Receive additional tips on having COVID-19 conversations with families.

"COVID-19 Crucial Conversations Campaign" helps healthcare professionals counsel patients on COVID-19 vaccines. Register for upcoming trainings or view archived sessions at the <u>campaign webpage</u>.

### Thank you.

We acknowledge your ongoing efforts to protect children through vaccination. We appreciate your continued partnership in ensuring children and their families are safe and healthy.

# AB 1797 Resources

- FAQs page
- Short <u>video</u> highlighting benefits of using CAIR
- Doses administered report
  - See <u>CAIR user guides</u> to enter doses correctly

## Prepare for the New Immunization Registry Requirement

## What is the new requirement?

AB 1797, a California bill effective January 1, 2023, requires providers to enter immunizations they administer as well as a patient's race and ethnicity into a California immunization registry (CAIR or HealthyFutures/RIDE).



## Where can I learn more? Visit <u>bit.ly/AB1797FAQ</u>.



### **Enroll Now**

There are many benefits to participating in an immunization registry. To learn more, visit <u>bit.ly/CAIRvideo</u> or to start the enrollment process, visit <u>cairweb.org</u>.

Providers in Alpine, Amador, Calaveras, Mariposa, Merced, San Joaquin, Stanislaus, or Tuolumne counties will need to enroll in Healthy Futures/RIDE (www.myhealthyfutures.org). For assistance, contact the Healthy Futures/RIDE Help Desk at (209) 468-2292 or support@myhealthyfutures.org.



We are here to support you along the way Questions? <u>CAIRHelpdesk@cdph.ca.gov</u> Phone: 800-578-7889

## AB 1797 Communication Flyer



# **Digital Vaccine Record**

What digital records can I access from the

There are two types of records you can access

COVID-19 QR code that (when scanned by

a SMART Health Card reader) will display

the same information as your paper CDC

vaccine card: your name, date of birth,

· Record of all your vaccinations that were

reported by pharmacies and healthcare

providers to CAIR. Note that your historical

vaccinations may not have been reported

OCDPH

IMM-1461 (3/9/23)

vaccination dates, and vaccines.

### GET YOUR DIGITAL VACCINE RECORD



**DVR Portal?** 

to CAIR

from the DVR Portal:

What is a Digital Vaccine Record (DVR)? Your Digital Vaccine Record (DVR) is an electronic vaccination record from the California Immunization Registry (CAIR) and is an official record of the state of California.

What information does the DVR include? The DVR has your name, date of birth, vaccination dates, and the vaccines you received.

## Where do I access my Digital Vaccine Record?

Visit myvaccinerecord.cdph.ca.gov to access your record. You will need to enter your first and last name, date of birth, and mobile number or email address. You will create a PIN which will be required to obtain your DVR when the link to your record is provided to you.

For more DVR questions, visit myvaccinerecord.cdph.ca.gov/faq or call 1-833-422-4255 (open M-F 8AM-8PM, SA-SU 8AM-5PM).

California Department of Public Health, Immunization Branch

## **DVR Fact Sheet**

## OBTENGA SU REGISTRO DIGITAL DE VACUNACIÓN



el Portal DVR?

y las vacunas

¿Qué registros digitales puedo acceder desde

Hay dos tipos de registros a los que puede

Código QR de COVID-19 que (cuando es

· Registro de todas las vacunas que

informaron las farmacias y otros

proveedores de salud a CAIR. Tome en

cuenta que es posible que su historial de

vacunación no se haya ingresado a CAIR.

IMM-14615 (3/30/23)

escaneado por un lector de tarjetas SMART

Health) mostrará la misma información que

su tarjeta de papel de los CDC: su nombre,

fecha de nacimiento, fechas de vacunación

acceder desde el Portal DVR:

Registro Digital de Vacunación (DVR) Su Registro Digital de Vacunación (DVR, por sus siglas en inglés) es un registro electrónico de vacunación procedente del Registro de Vacunación de California (CAIR, por sus siglas en inglés) y es un registro oficial del estado de

California. ¿Qué información incluye el DVR? El DVR tiene su nombre, fecha de nacimiento, fechas de vacunación y las vacunas que

recibió. ¿Dónde accedo mi Registro Digital de Vacunación? Visite myvaccinerecord.cdph.ca.gov para acceder su registro. Necesita ingresar su

primer nombre y apellido, fecha de nacimiento y número de celular o correo electrónico. Necesitará crear un PIN para poder obtener su DVR cuando se le proporcione el enlace a su registro.

Para más preguntas sobre el DVR, visite myvaccinerecord.cdph.ca.gov/faq-es/ o llame al 1-833-422-4255 (L—V 8AM-8PM, S-D 8AM-5PM).

California Department of Public Health, Immunization Branch



## Additional languages still to come!










During today's webinar, please use the Q&A panel to ask your questions so CDPH subject matter experts can respond directly.





Resource links will be dropped into, "Chat"



## Stay informed! Provider Resources on <u>eziz.org</u> and <u>eziz.org/covid</u>



## Updates for Providers





Training Calendar

### Alerts:

### Vaccine Updates

 Authorization and Recommendation of Bivalent mRNA COVID-19 Vaccines as Primary Series 4/21

### **Clinical Job Aids**

- COVID-19 Vaccine Products Guide, Updated 4/20
- COVID-19 Vaccination Schedule (Timing Guide), Updated 4/7 Spanish version: Calendario de la Vacuna COVID-19 (Guía de Tiempo) Updated 3/17
- Interim Clinical Considerations for Use of COVID-19 Vaccines (CDC)
- Recommending COVID-19 Vaccination: Clinical Talking Points for Providers of Pediatric Services 4/5

### **Provider Operations**

- COVID-19 Provider Operations Manual (POM) Updated 4/10
- Provider Startup Worksheet

### Now Enrolling Providers of Pediatric Services

- Find Information on How to Enroll
- Dispelling Provider Myths About Joining the California COVID-19 Vaccination
  Program
- Welcome VFC Providers | Flyer | VFC vs. COVID Programs



# **California Providers Stay Informed!**



## Immunization Branch Listserv Emails Sign-Up

EZIZ Update				
April /	Immunization Branch			
National Infant Immunization and World Immunization Week is April 24-30!				
National Infant Immunization Week	Join us in observing <u>National Infant</u> <u>Immunization Week</u> (NIIW) and <u>World</u> <u>Immunization Week</u> ! Let's recognize our collective achievements in protecting infants and young children			

Immunization Week (NIIW) and World Immunization Week! Let's recognize our collective achievements in protecting infants and young children from <u>14 vaccine-preventable diseases</u>, drastically reducing death and disability in the U.S. This is also a great opportunity to remind families to stay on track for their children's routine checkups and recommended vaccinations; <u>Don't Wait – Vaccinate</u>!

On-time vaccination is critical to provide protection against potentially lifethreatening diseases. Before the back-to-school immunization rush, take time now to ensure that infants and toddlers are up to date with their vaccines.

## COVID-19 Vaccine Provider Listserv Emails: Please email <u>blanca.corona@cdph.ca.gov</u>

### For Providers

California COVID-19 Vaccination Program Update

### April 21, 2023

### Authorization and Recommendation of Bivalent mRNA COVID-19 Vaccines as Primary Series

#### This week, FDA authorized and CDC recommended

- The use of Moderna and Pfizer Bivalent COVID-19 vaccine for primary series use for individuals 6 months and older.
- Additional doses of these vaccines for certain populations.

Monovalent Pfizer and Moderna vaccines are no longer authorized by FDA or recommended by CDC for use in the United States.

Therefore, providers are no longer able to order Pfizer and Moderna monovalent mRNA vaccines doses and should only use bivalent vaccine for all doses administered to individuals 6 months of age and older.

#### Moderna and Pfizer Bivalent Vaccine Recommendations:

- Individuals ages 6 years and older who have already received an updated (bivalent) mRNA vaccine do not need to take any action unless they are 65 years or older or immunocompromised.
- CDC's new recommendations allow an additional updated (bivalent) vaccine dose for adults ages 65 years and older and additional doses for people who are immunocompromised.
- CDC recommends that everyone ages 6 years and older receive an updated (bivalent) mRNA COVID-19 vaccine, regardless of whether they previously completed their (monovalent) primary series.
- For young children, multiple doses continue to be recommended and will vary by age, vaccine, and which vaccines were previously received. See the updated Pfizer-BioNTech COVID-19 Vaccine Factsheet and the updated Moderna COVID-19 Vaccine Factsheet for details.



Special Thanks to Today's Presenters: Samantha Johnston, MD, MPH Michael Powell, MSc Terisha Gamboa, MPH



# Thank you for joining CDPH for Afternoon TEAch!



